The Potential Utility of Aripiprazole Augmentation for Major Depressive Disorder with Mixed Features Specifier: A Retrospective Study

키워드

참고문헌 (44)

1. Rush AJ, "STAR*D : what have we learned", Am J Psychiatry, 164, pp.201~204 (2007)
2. Young Sup Woo, "Dose Trends of Aripiprazole from 2004 to 2014 in Psychiatric Inpatients in Korea", Clinical Psychopharmacology and Neuroscience, 15(2), pp.177~180 (2017), 대한정신약물학회[DOI]
3. Changsu Han, "A Pharmacogenomic-based Antidepressant Treatment for Patients with Major Depressive Disorder: Results from an 8-week, Randomized, Single-blinded Clinical Trial", Clinical Psychopharmacology and Neuroscience, 16(4), pp.469~480 (2018), 대한정신약물학회[DOI]
4. Dold M, "Clinical characteristics and treatment outcomes of patients with major depressive disorder and comorbid anxiety disorders-results from a European multicenter study", J Psychiatr Res, 91, pp.1~13 (2017)
5. McIntyre RS, "The prevalence and illness characteristics of DSM-5-defined"mixed feature specifier"in adults with major depressive disorder and bipolar disorder : results from the International Mood Disorders Collaborative Project", J Affect Disord, 172, pp.259~264 (2015)
6. Vázquez GH, "Mixed symptoms in major depressive and bipolar disorders : a systematic review", J Affect Disord, 225, pp.756~760 (2018)
7. Narei Hong, "Improving the Screening Instrument of Bipolar Spectrum Disorders: Weighted Korean Version of the Mood Disorder Questionnaire", Clinical Psychopharmacology and Neuroscience, 16(3), pp.333~338 (2018), 대한정신약물학회[DOI]
8. Sheng Min Wang, "Second Generation Antipsychotics in the Treatment of Major Depressive Disorder: An Update", 전남의대학술지, 52(3), pp.159~172 (2016), 의과학연구소
9. Jeong Seok Seo, "Korean Medication Algorithm for Depressive Disorders 2017: Third Revision", Clinical Psychopharmacology and Neuroscience, 16(1), pp.67~87 (2018), 대한정신약물학회[DOI]
10. Pae CU, "Aripiprazole in the treatment of depressive and anxiety disorders : a review of current evidence", CNS Drugs, 22, pp.367~388 (2008)
11. Nelson JC, "Effects of aripiprazole adjunctive to standard antidepressant treatment on the core symptoms of depression : a post-hoc, pooled analysis of two large, placebo-controlled studies", J Affect Disord, 120, pp.133~140 (2010)
12. Trivedi MH, "Adjunctive aripiprazole in major depressive disorder : analysis of efficacy and safety in patients with anxious and atypical features", J Clin Psychiatry, 69, pp.1928~1936 (2008)
13. Stewart TD, "Effect of symptom severity on efficacy and safety of aripiprazole adjunctive to antidepressant monotherapy in major depressive disorder : a pooled analysis", J Affect Disord, 162, pp.20~25 (2014)
14. Pae CU, "Clinical issues in use of atypical antipsychotics for depressed patients", CNS Drugs, 27(Suppl 1), pp.S39~S45 (2013)
15. Strejilevich SA, "Dopamine sudden depletion as a model for mixed depression", Med Hypotheses, 78, pp.107~112 (2012)
16. Conway CR, "Antidepressant response to aripiprazole augmentation associated with enhanced FDOPA utilization in striatum : a preliminary PET study", Psychiatry Res, 221, pp.231~239 (2014)
17. American Psychiatric Association, "Diagnostic and statistical manual of mental disorders" (2013), American Psychiatric Publishing
18. Montgomery SA, "A new depression scale designed to be sensitive to change", Br J Psychiatry, 134, pp.382~389 (1979)
19. Young RC, "A rating scale for mania : reliability, validity and sensitivity", Br J Psychiatry, 133, pp.429~435 (1978)
20. Sheehan KH, "Assessing treatment effects in clinical trials with the discan metric of the Sheehan Disability Scale", Int Clin Psychopharmacol, 23, pp.70~83 (2008)
21. Guy W, "ECDEU assessment manual for psychopharmacology", U.S. Department of Health Education and Welfare, ~ (1976)
22. Stahl SM, "Guidelines for the recognition and management of mixed depression", CNS Spectr, 22, pp.203~219 (2017)
23. Bandelow B, "What is the threshold for symptomatic response and remission for major depressive disorder, panic disorder, social anxiety disorder, and generalized anxiety disorder", J Clin Psychiatry, 67, pp.1428~1434 (2006)
24. Takeshima M, "Treating mixed mania", hypomania : a review and synthesis of the evidence, 2017, pp.22, 177~185
25. Suppes T, "Efficacy and safety of aripiprazole in subpopulations with acute manic or mixed episodes of bipolar I disorder", J Affect Disord, 107, pp.145~154 (2008)
26. Kamijima K, "Aripiprazole augmentation to antidepressant therapy in Japanese patients with major depressive disorder : a randomized, double-blind, placebo-controlled study(ADMIRE study)", J Affect Disord, 151, pp.899~905 (2013)
27. Kamijima K, "Real-world effectiveness and safety of aripiprazole augmentation therapy in patients with major depressive disorder", Curr Med Res Opin, 34, pp.2105~2112 (2018)
28. Ozaki N, "Efficacy of aripiprazole augmentation in Japanese patients with major depressive disorder: a subgroup analysis and Montgomery-Åsberg Depression Rating Scale and Hamilton Rating Scale for Depression item analyses of the Aripiprazole Depression Multicenter Efficacy study", Psychiatry Clin Neurosci, 69, pp.34~42 (2015)
29. Berman RM, "Aripiprazole augmentation in major depressive disorder : a double-blind, placebo-controlled study in patients with inadequate response to antidepressants", CNS Spectr, 14, pp.197~206 (2009)
30. Berman RM, "The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder : a multicenter, randomized, double-blind, placebo-controlled study", J Clin Psychiatry, 68, pp.843~853 (2007)
31. Marcus RN, "The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder : a second multicenter, randomized, double-blind, placebo-controlled study", J Clin Psychopharmacol, 28, pp.156~165 (2008)
32. Jon DI, "Augmentation of aripiprazole for depressed patients with an inadequate response to antidepressant treatment : a 6-week prospective, open-label, multicenter study", Clin Neuropharmacol, 36, pp.157~161 (2013)
33. Pae CU, "Aripiprazole augmentation for treatment of patients with chronic or recurrent major depressive disorder : a 12-week prospective open-label multicentre study", Int Clin Psychopharmacol, 28, pp.322~329 (2013)
34. Han C, "Aripiprazole augmentation, antidepressant combination or switching therapy in patients with major depressive disorder who are partial-or non-responsive to current antidepressants : a multi-center, naturalistic study", J Psychiatr Res, 49, pp.75~82 (2014)
35. Han C, "Aripiprazole augmentation versus antidepressant switching for patients with major depressive disorder: a 6-week, randomized, rater-blinded, prospective study", J Psychiatr Res, 66-67, pp.84~94 (2015)
36. Pae CU, "Aripiprazole augmentation for major depressive disorder : dosing patterns in a naturalistic treatment setting", Int Clin Psychopharmacol, 29, pp.116~119 (2014)
37. Kelly T, "The utility of low-dose aripiprazole for the treatment of bipolar II and bipolar NOS depression", J Clin Psychopharmacol, 37, pp.99~101 (2017)
38. Thase ME, "Aripiprazole monotherapy in nonpsychotic bipolar I depression : results of 2 randomized, placebo-controlled studies", J Clin Psychopharmacol, 28, pp.13~20 (2008)
39. Suppes T, "Lurasidone for the treatment of major depressive disorder with mixed features : a randomized, double-blind, placebo-controlled study", Am J Psychiatry, 173, pp.400~407 (2016)
40. Suppes T, "Lurasidone adjunctive with lithium or valproate for bipolar depression : a placebo-controlled trial utilizing prospective and retrospective enrolment cohorts", J Psychiatr Res, 78, pp.86~93 (2016)
41. DOPA, "PLoS One", 2012, e46488~
42. Sparshatt A, "A systematic review of aripiprazole--dose, plasma concentration, receptor occupancy, and response : implications for therapeutic drug monitoring", J Clin Psychiatry, 71, pp.1447~1456 (2010)
43. raclopride, "Neuropsychopharmacology", 2002, 248~259
44. Ji L, "Single-step assays to analyze CYP2D6 gene polymorphisms in Asians : allele frequencies and a novel *14B allele in mainland Chinese", Clin Chem, 48, pp.983~988 (2002)

관련 논문AI추천